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Squamous cell carcinoma (SCC) of the neovagina after genital reconstruction surgery is a rare occurrence with only very
few cases published up to the present. We report a case of a 43-year-old transgender woman who developed neovaginal SCC
23 years after vaginoplasty. The patient tested positive for high-risk human papillomavirus (HPV). At the time of diagnosis,
radiological investigations revealed already existing lymph node and osseous metastases.The treatment consisted of various cycles
of chemotherapy and radiation therapy. Unfortunately, the formation of additional metastases, including cerebral, pulmonary, and
hepatic metastases, could not be prevented. After comparing the literature on the topic, we conclude that neovaginal carcinoma
often appears years and decades after genital reconstruction surgery. We therefore recommend the continuation of regular clinical
follow-up for transgender women after postoperative follow-up is completed.With this approach, potential lesionsmay be detected
at an earlier stage and a better outcome may be achieved. Follow-up should include neovaginal examination and cytological smear
testing. At a later age, we recommend additional regular prostate-specific antigen (PSA) testing and digital rectal examination
(DRE). Moreover, transgender women are advised to take part in mammography screening starting at the age of 50, especially
when additional risk factors are present.
1. Introduction
SCC of the neovagina is a rare finding [1]. However, as genital
reconstruction surgery becomes more accessible and is more
frequently performed, awareness of the disease is important
[2]. Vaginoplasty by penile or in combination with scrotal
skin inversion is the commonly used technique in male-
to-female reconstruction surgery [3]. Further methods of
neovaginal construction include transposition of peritoneal,
intestinal, and full or split skin grafts. These methods are also
used for vaginoplasty after resection of a natural vagina or in
womenwith vaginal agenesis as a result ofMayer-Rokitansky-
Ku¨ster-Hauser syndrome [3, 4].
In this report, we present a case of neovaginal SCC
arising in an HIV-positive transgender woman, which has
also been mentioned in a recent publication by Grosse et
al. [5]. The tumour developed 23 years after vaginoplasty,
presumably as a consequence of high-risk HPV infection of
the penile skin. In the literature review, a comparison was
made between the present case and the three cases of SCC
in the neovagina of transgender women published to date
[6–8]. This was collated with a case series of 16 neovaginal
carcinoma in nontransgender women with primary vaginal
malformations, as reviewed by Steiner et al. [4].
2. Case Report
We report the case of a 43-year-old HIV-positive transgender
woman. The patient presented at her physician in December
2015 after discovering intermittent vaginal bleeding for 4
weeks. For the same period of time, she stated a foul-smelling
vaginal discharge and occasional pain in the genital region
that increased while walking.
Thepatient had undergone genital reconstruction surgery
inThailand at the age of 21 and had been on hormone therapy
ever since. Unfortunately, the documents of the procedure
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Figure 1
were unavailable. However, it seems highly probable that the
neovagina was formed using penile and scrotal skin since
clinical examination indicated a full skin graft. In addition,
combined penile and scrotal skin inversion is the most
frequently performed vaginoplasty in transgender women,
as mentioned above. The first 11 years after the creation
of the neovagina remained uneventful. The following year,
the patient was diagnosed with an HIV infection CDC-
classification stadium B3. She then received antiretroviral
therapy, which she interrupted twice but with negative viral
load at time of presentation. Several months after the HIV
diagnosis, the patient suffered from a cohabitational injury,
which was revised subsequently.
With the history of vaginal bleeding, her physician
referred the patient to the gynaecology department of the
University Hospital Zurich. Vaginal and speculum exami-
nation revealed an ulcerative lesion, which was painful on
palpation and started bleeding in contact with a swab. The
patient denied recent cohabitations and vaginal trauma.
The swab of the lesion revealed a high-grade squamous
intraepithelial lesion (HSIL). Subsequent MRI showed blood
in the neovagina and could not exclude a neovaginal tumour.
Nevertheless, no extravaginal masses or enlarged lymph
nodes were detectable. PET-CT scanning was performed
and revealed a distinctly progressive tumour at the apical
anterior wall of the neovagina with a wall thickness of 1.3 cm
(Figure 1). The mass was highly FDG-active and infiltrated
the neovagina in a craniocaudal extension of at least 4.6 cm.
The scan also showed a slightly enlarged left inguinal lymph
node compared to theMRI scan performed before.Moreover,
multiple FDG-active osseous metastases were visible, located
at the 5th right lateral rib, the 3th lumbar vertebral body,
and the right side of the sacral bone (Figure 2). Fine-needle
biopsy confirmed the diagnosis of a high-grade squamous
carcinoma.
In the given palliative situation, concomitant chemora-
diotherapy was started with the aim of gaining locore-
gional tumour control. 6 cycles of cisplatin chemotherapy
and percutaneous radiation therapy were conducted on the
primary lesion, the pelvic lymph system, and the osseous
metastases. This was followed by another 6 cycles of first-line
chemotherapy. The patient already suffered from impaired
general condition aside from the known comorbidities such
as HIV infection. For this reason, the gynaecological tumour
Figure 2
board discouraged a more aggressive chemotherapy usu-
ally applied in case of metastatic penile cancer. Six cycles
of carboplatin/paclitaxel and concomitant bone protection
(denosumab) were suggested instead. The PET-MRI scan
after completion of chemotherapy showed a mixed response.
It included regression of the primary lesion, a progressive
hepatic metastasis, small lung, and several additional osseous
metastases. Hence, selective internal radiation therapy was
performed on the right hepatic lobe. A further approach
was made, consisting of percutaneous radiotherapy on the
osseous metastasis of the scapula. Unfortunately, continuous
progression of the hepatic, osseous, and pulmonary metas-
tases was visible in a PET-CT 2 weeks later, and the options of
further treatmentwere profoundly discussed. Retrospectively
performed PCR of the tissue sample, which was gained at
the time of diagnostic biopsy, confirmed infection with high-
risk HPV type 51. At this time, the patient was already in
reduced general condition and did not qualify for another
combination chemotherapy. Nevertheless, the patient explic-
itly wished to proceed with systemic therapy. A cycle of more
tolerable topotecan monotherapy was therefore attempted,
analogous to the treatment of SCC of the cervix. In addition,
radiotherapy on the osseousmetastaseswas continued.When
the patient started to perceive dizziness shortly afterwards, a
cystic cerebellar metastasis with partial compression of the
4
th ventricle was detected by MRI scan. To ease her symp-
toms, suboccipital craniotomy was performed with macro-
scopically complete resection of the lesion. Histopathology
confirmed the diagnosis of a keratinizing SCC metastasis.
At this point, our patient was, regrettably, in terminal stage.
She was transferred to a Palliative Care Center, and we made
efforts to relieve her from pain as much as possible. Shortly
afterwards, during the process of this report, our patient
passed away, 2 years after primary tumour diagnosis.
3. Review of the Literature
To our best knowledge, only 4 cases of neovaginal SCC in
transgender women after genital reconstruction surgery have
been published to date, including our patient’s medical record
[6–8].The age at reconstruction was between 21 and 33 years,
with a median of 27 years. In all the vaginoplasties, skin
grafts were used to create the cavity of the neovagina. In two
cases, the skin was taken from the penis and scrotum, which
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Table 1: Age at reconstruction and diagnosis; time between procedure, symptoms, and physical examination.
Reference
Age at
reconstruction
(years)
Procedure
Age at
diagnosis
(years)
Years/between Symptoms Physicalexamination
Y. Harder et al.
[6] 24
Penile and
scrotal skin
inversion
42 18
Increasing
vaginal
discharge, fistula
Mass, posterior
vagina
H. Fernandes et
al. [7] 30, 31 Skin graft 53 21
Bloody,
foul-smelling
discharge
4 cm necrotic
mass, apex of
neovagina
J. Bollo et al. [8] 33
Penile and
scrotal skin
inversion
78 45
Genital
discomfort,
vaginal
discharge
Bulky mass,
posterior vagina
Present case 21
Presumably
penile and
scrotal skin
inversion
43 22
Vaginal
bleeding,
foul-smelling
discharge
4.6 cm
ulcerative
tumour, apical
anterior vagina
was presumably also the case in our patient’s surgery. The
4
th patient initially also underwent vaginoplasty by penile
and scrotal skin inversion. Besides, she had another surgery
a year later with the aim of creating a deeper cavity of
the neovagina. An abdominoperineal skin graft was used
for this purpose. Unfortunately, it is unknown whether the
first implant was excised completely or whether the second
graft was added to the already existing neovaginal pouch.
After 10 years, another two smaller revisions were performed.
The age at diagnosis ranged from 42 to 78 years, with a
median of 54 years. The latency period between the age at
reconstruction and the age when diagnosed with cancer was
between 18 and 45 years, with a median of 26.5 years. All
patients reported vaginal discharge as first symptom. Two
patients had an additional fistula, and two patients also stated
vaginal bleeding. One patient claimed genital discomfort as
another symptom. Physical examination revealed tumour
masses, which were necrotic in one case and ulcerative in
another. In two cases, the tumour was located at the posterior
part of the neovagina. In a further case, it was situated at the
apex and in our case the location of the tumour was the apical
anterior wall of the neovagina (Table 1) [6–8].
The primary treatment of the neovaginal lesions was in
two cases a combined chemoradiotherapy and in one case a
tumour exenteration with subsequent chemotherapy. In the
4
th case, the neovagina was fully resected, with additional
combined chemoradiotherapy. All four cancerous lesions
were confirmed by histological examination to be due to
SCC. Two patients were diagnosed with moderately differ-
entiated skin cancer, one suffered from a well-differentiated
carcinoma, and our case turned out to be a high-grade SCC.
In two cases, the lymph nodes showed no enlargement. Our
patient’s lymph node biopsy was positive for cell aberration
and the 4th patient’s lymph node state was notmentioned.The
first two transgender women had a recurrence-free follow-
up of 2 and 2.5 years, respectively. The patient with the well-
differentiated carcinoma died after 2 months due to sepsis
and multiorgan failure. And our patient had an aggravating
clinical course over a time period of 2 years, including
the development of multiple metastases, which she did not
survive either. PCR of the neovaginal lesion biopsies was
positive for HPV in three cases. Twice, a high-risk HPV
type was detected (in one case type 16 and in our case type
51). In the 3rd case, the HPV type was not specified in the
paper. Unfortunately, PCR was not performed in the 4th case.
Nevertheless, immunohistochemistry for p16 turned out to
be negative (Table 2) [6–8].
Based on the occurrence of HPV in three of the four
published cases, it might be reasonably assumed that HPV
plays a significant role in the development of SCC of the
neovagina constructed by penile skin. This applies especially
to high-risk types of HPV, as will be discussed in more detail.
In their case report “Carcinoma of the Neovagina: Case
Report and Review of the Literature”, Steiner et al. analysed
16 cases of neovaginal carcinoma [4]. The patients were
nontransgender women who were born with vaginal malfor-
mations. In their literature review, the women had mostly
been operated at a very young age, whereby a functional
neovagina was created. The median age at vaginoplasty was
18.1 years, whereas it was 27 years in our study. Moreover,
the nontransgender women were also younger at the time
of diagnosis, with a median of 36 years. In comparison, our
patients were on average 54 years old when diagnosed with
cancer. Thus, the latency period was shorter in their study,
with a median of 17.4 years compared to the transgender
women, who had an average latency period of 26.5 years.
Ten of the 16 nontransgender patients reported vaginal
bleeding and four also claimed discharge. In contrast, all
of the transgender women named vaginal discharge as first
symptom and two of the four also reported vaginal bleeding.
The tumours of the nontransgender women were mainly
located at the posterior wall and in two cases the lesions
had developed at the apex of the vagina. This is consistent
with our finding (two tumours at the posterior wall, one
tumour at the apex, and one at the apical anterior wall)
[4, 6–8].
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Table 2: Primary treatment, histopathology of tumours and lymph nodes, results of treatment, and additional clinical data.
Reference Primary treatment Pathology Lymphnodes Result/therapy Additional clinical data
Y. Harder
et al. [6]
Total resection of
neovagina followed
by combined
chemoradiotherapy
HPV-
induced
squamous
cell
carcinoma of
the penis
No
enlargement
Disease-free
follow-up for 2.5
years
Previous history of
chronic venereal warts
(low-risk HPV infection)
H.
Fernandes
et al. [7]
Combined
chemoradiotherapy
Moderately
differentiated
squamous
cell
carcinoma
No
information
Disease-free
follow-up for at
least 2 years
No history of STIs
including warts, negative
p16
immunohistochemistry
J. Bollo et
al. [8]
Tumour exenteration
and chemotherapy
Well-
differentiated
squamous
cell
carcinoma
No
enlargement
Death after 2
months
High-risk HPV (type 16)
infection, death due to
sepsis and multi-organ
failure
Present
case
Combined
chemoradiotherapy
High grade
squamous
carcinoma
positive Death 2 yearsafter diagnosis
High-risk HPV (type 51)
infection, HIV infection,
multiple osseous
metastases at time of
diagnosis
In the study by Steiner et al., radiation was used in eight
of the 16 nontransgender patients as the primary choice of
treatment. A primary surgical approach was chosen in six
cases, and in two cases there was no information regard-
ing the primary treatment. In comparison, the transgender
women were treated with combined chemoradiotherapy in
half of the cases, whereas surgery was chosen as the primary
treatment in the other half. Steiner et al. report that diverse
methods of vaginoplasty were carried out. Skin transplants
were used in seven cases, intestinal grafts in four cases, and
peritoneal and dura tissue each in one case. Two women
obtained vaginal construction without the use of a graft and
once the transplant tissue was not described. Histopathology
of the lesions identified 11 cases of SCC and five cases of
adenocarcinoma. The tumour tissue in all four intestinal
transplants turned out to be due to an adenocarcinoma. The
5
th case of adenocarcinoma, however, developed in a woman
whose neovagina had been created using a skin graft only.
Ten of the 11 SCC evolved from skin, peritoneal and dura
grafts, as well as from neovaginal tissue formed by vaginal
traction (without graft).The 11th case appeared in the woman
whose transplant tissue is unknown. However, the genital
reconstruction surgeries of the four transgender women were
performed using skin grafts only, and the biopsies of the
lesions led to the diagnosis of SCC in all cases. In one of
the nontransgender women in the study by Steiner et al., the
lymph node state showed a pathological finding. In two cases,
the examined cells showed no change in differentiation, and
as for the other 13 women there was no information on the
lymph node state available. In our study, abnormality of the
lymph node tissue was detected in one transgender patient.
Furthermore, there were two negative findings and one case
without information on the topic. Five of the nontransgender
women with vaginal agenesis were at time of publication
of their cases in a disease-free follow-up state for several
months. Three of the women died due to their condition and
two women suffered from a recurrence within only a few
months. Unfortunately, the clinical course of the other five
nontransgender women is unknown. In comparison, two of
the transgender women, including our patient, succumbed to
their diseases. The other two, however, showed a disease-free
interval of at least 2 years prior to the publication of their
cases. Whereas HPV infection was present in three of the
four transgender women, Steiner et al. did not detect any low-
grade or high-grade HPV infection in the biopsy material of
their patient. Unfortunately, the matter of HPV concerning
the other 15 nontransgender women was not discussed in the
paper [4, 6–8].
4. Discussion
As penile skin inversion is the most frequently applied
technique in male-to-female reconstruction surgery, the
original tissue of the newly formed vagina is exposed to a
different environment [9]. The recently published study by
Grosse et al., which examined the cytology of 20 neovaginal
tissue samples in transgender and nontransgender women,
discovered inflammation to be present in 40% of the cases
[5].The abnormal exposure of the neovaginal tissue therefore
seems to be a risk factor for chronic irritationwith subsequent
inflammation and infection of the neovagina [2].The regular
use of a prosthesis for neovaginal dilatation and the higher
neovaginal pH compared to nontransgender women were
found to be further risk factors [2, 4]. Consequently, the graft
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tissue may be susceptible to sexually transmitted diseases
(STDs) as well.
Hiroi et al. summarized 11 cases of neovaginal carcino-
genesis in nontransgender women after vaginoplasty due
to vaginal agenesis [10]. When interpreting their results, it
occurred to them that all of the patients with skin transplants
developed SCC of the neovagina. In contrast, every case of
intestinal neovaginal graft mutated into an adenocarcinoma.
These findings led to their conclusion that the tissue used in
vaginoplasty has considerable influence on the direction of
pathogenesis and the resulting malignant manifestation [10].
As explained above, the study of Steiner et al. showed similar
results: All of the four women with intestinal grafts developed
an adenocarcinoma, whereas SCC evolved in eleven of
the twelve women, whose neovaginas were constructed by
vaginal traction (no graft) or the use of skin, peritoneal
and dura grafts. Nevertheless, one case of neovaginal skin
transplant turned into an adenocarcinoma. However, the
woman did present with a rectoneovaginal fistula at the time
of diagnosis. Since the tumour was located at the posterior
wall of the neovagina, it may be assumed that it evolved from
the intestinal tissue of the colon rather than the neovaginal
skin graft [4].
Studies have stated a high prevalence of sexually transmit-
ted infections in transgender women [11]. These include HIV
and HPV, which is the most frequent sexually transmitted
infection [11–15]. Furthermore, it was reported that infection
with a high-risk HPV type is not only essential to cervical
carcinogenesis but also associated with anogenital and penile
malignancies [16, 17]. Penile carcinomas are most commonly
SCC emerging from penile intraepithelial neoplasia precur-
sor lesions. In the formation of this tumour type, a high-
risk HPV infection is assumed to be the cause of malignant
transformation in about 40-50% of the cases [16, 17]. Anal
carcinogenesis studies have shown that high-risk HPV, pre-
dominantly HPV type 16, is associated with about 90% of
anal cancers [16]. These findings suggest that HPV infection
plays an important role inmale genital carcinogenesis as well.
Since, histologically, neovaginal SCC of transgender women
are SCC of the penile and scrotal skin grafts, the same applies
to transgender women.
In contrast to nontransgender females, transgender
women receive their neovaginal transplants almost exclu-
sively from skin grafts [2, 3]. And since skin transplants seem
likely to transition into SCC rather than adenocarcinoma,
as previously discussed, HPV-associated neovaginal carcino-
genesis might figure more prominently in transgender than
nontransgender women.This is due to the fact that nontrans-
genderwomenwhowere bornwith vaginal anomalies usually
receive intestinal transplants, which are more likely to change
into adenocarcinoma [4].
In addition, transgender women are at high risk of
acquiring an HPV infection, since the prevalence of HPV
is generally high in the male genital region (up to 76%
[9]). Moreover, the majority of transgender women have a
hetero- or bisexual orientation and are therefore likely to have
sexual contacts with men [2, 9]. As unexpected pregnancy is
not a risk, sexual protection may be used to a lesser extent
than in nontransgender women. HPV and other STDs might
therefore be more easily transmitted.
A recently published study, which analysed the preva-
lence of HPV infection in transsexual men and women,
found HPV infection rate of 52.4% in the examined male-to-
female transgender cohort [14]. Furthermore, and even more
notably, 100% of the HPV-positive transgender women had
been infected with at least one oncogenic HPV genotype.The
study also stated that, in more than a 3rd (35.7%) of the HPV-
positive transgender individuals, vaccine-preventable HPV
genotypes were detected. This demonstrates the importance
of HPV vaccinations in the mentioned patient cohort [14].
However, prevention of neovaginal carcinogenesis in
transgender women should be extended beyond the recom-
mended vaccination program. Weyers et al. reported that
only 4% of the examined individuals ever had a gynaeco-
logical exam after follow-up of vaginoplasty was completed
[2]. As previously discussed, our observations suggest that
neovaginal tumour masses are often located at the posterior
wall or the apex of the neovagina. Detection by the patients
themselves might therefore be a difficult matter, especially at
an early stage of disease. At the same time, speculum and
digital neovaginal exams were found to be well tolerated by
transgender women [2]. Furthermore, regular gynaecological
examination was considered by the majority (84%) to be an
appreciated follow-up procedure after genital reconstruction
surgery [2]. We therefore recommend the continuation of
annual follow-up for transgender women after postoperative
follow-up is completed, including speculum and digital
neovaginal examination.
Although it is not generally recommended in medical
checkup after genital reconstruction surgery, the new guide-
lines of the endocrinology society suggest routine cancer
screening for transgender women [18]. Following the Swiss
guidelines for nontransgender women, we primarily recom-
mend cytologic smear testing every three years, starting at age
21 until patients reach the age of 70 [19].
As transgenderwomenusually take feminizing hormones
for years, a risk assessment for cardiovascular disease is
recommended [2, 20]. Particularly the incidence of throm-
boembolic events may be a serious complication in patients
with estrogen substitution therapy [18]. A further matter
to be discussed in the individual patient’s follow-up is
mammography screening. Long-term use of estrogen may
increase the risk of breast cancer development in transgender
women, who are usually less affected than nontransgender
women [2, 20]. We therefore suggest routine mammography
screening every two years, starting at the age of 50 until 70,
as it is clinical practice in University Hospital Zurich for
nontransgender women [21]. Particularly individuals with a
positive family history or further risk factors for breast cancer
are advised to take part in regular screening [20, 21].
The prostate is generally left in place when vaginoplasty is
performed [2]. Following the guidelines and clinical practice
of University Hospital Zurich for cisgender men, we rec-
ommend PSA testing and DRE every four years (for PSA
levels < 1ng/ml) in addition to the annual follow-up, when
transgender women reach the age of 45 years [22].
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5. Conclusion
In conclusion of our findings, we state that carcinogenesis
in transgender women after genital reconstruction surgery
may develop after a long latency period and with rapid
progression. Adequate patient’s instruction is therefore an
important matter. We advise gynaecologists to encourage
transgender women to undergo a continuous annual follow-
up after postoperative follow-up is completed. Neovaginal
carcinoma, as a rare condition, has been observed to be
frequently located at the apex or the posterior wall of
the neovagina. As a consequence, they may be difficult to
discover by the patients themselves. Through regular follow-
up, including neovaginal examination and cytological smear
testing, the patients may be diagnosed at an earlier stage
of carcinogenesis. Hereby the outcome may be positively
affected. Considering the long-term hormonal substitution,
whichmost of the transgender womenmake use of, potential
thromboembolic events should be borne in mind. Starting
at the age of 50, transgender women should take part in
regular mammography screening, especially when additional
risk factors are present. As the prostate is mostly left in
place, regular PSA testing andDRE are valuable techniques in
prostate screening and should be added to the annual follow-
up when patients reach the age of 45.
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